• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Screening for cardiovascular disease marker in community health centers may reduce risk

By: NewMediaWire
July 23, 2025 at 08:00 AM EDT

(NewMediaWire) - July 23, 2025 - DALLAS — Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide.[1] Lp(a) is similar to low-density lipoprotein (LDL), or “bad” cholesterol, yet is caused by genetics and is not impacted by lifestyle modifications.

While it is estimated that 1 in 5 Americans have high Lp(a) levels, many people are not aware of their risk. Research has found less than 1% of people with atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries, are tested for Lp(a).[2]

The American Heart Association, a global force changing the future of health for all, has launched the Lp(a) Community Health Centers Discovery Project, supported by Novartis Pharmaceuticals Corporation, to increase awareness about Lp(a). Additionally, the initiative will focus on improving shared decision making between health care professionals and individuals within community health centers (CHCs) on the importance of Lp(a) screening and ASCVD risk management.

“A simple, one-time Lp(a) test can give lifelong insight about overall heart disease risk — especially for people with a family history or who are otherwise at increased risk,” said Kaavya Paruchuri, M.D., American Heart Association volunteer and clinical operations director of the cardiovascular medicine section and director of the Lipid Apheresis Unit, Preventive Cardiology, at Massachusetts General Hospital in Boston. “Community health centers are vital for making this important tool available to more people and helping individuals take control of their heart health.”

Ten CHCs throughout the U.S. signed onto the project in 2024, and 10 additional sites will be added this year. So far, participating CHCs have successfully added new Lp(a) screening processes resulting in increased testing at the sites. This reflects strong momentum for expanding Lp(a) testing access.

Current participating CHCs include:

  • Bay Area Community Health in Fremont, California
  • Bee Busy Wellness Center in Houston
  • Capital Area Health Network in Richmond, Virginia
  • El Centro Family Health in Española, New Mexico
  • Heart of Ohio Family Health Centers in Columbus, Ohio
  • Lone Star Family Health Center in Conroe, Texas
  • Southwest Community Health Center in Bridgeport, Connecticut
  • Spring Branch Community Health Center in Houston
  • The Chautauqua Center in Dunkirk, New York
  • Westside Family Health Center in Culver City, California

In 2023, the American Heart Association launched an initiative called the Lp(a) Discovery Project to improve the number of patients screened for Lp(a) through professional and patient education. This initiative gathered insights from 10 health systems across the country who have established Lp(a) testing processes. Lessons learned from this initiative will be used to drive improvements across CHCs participating in the Lp(a) Discovery Community Health Centers Project.  

Studies have shown that elevated Lp(a) increases risk for ASCVD-related events such as aortic stenosis, heart attack, peripheral artery disease and stroke.[3] Although treatment options for high Lp(a) are limited, some lifestyle changes and medication therapies can assist with lowering a person’s overall risk for heart disease.

A baseline survey conducted as part of the Lp(a) Discovery Project found few U.S. adults are aware of Lp(a), which is accompanied by lack of concern and urgency to have levels checked. U.S. adults are not linking elevated Lp(a) to cardiovascular risk, but when they do, it motivates them to talk to their doctor. Health care professionals are the top source of Lp(a) awareness; their recommendation and personal experience is key to considering getting Lp(a) levels checked.

Community Health Centers can express interest in participating in this initiative by completing the form at heart.org/LpaDiscovery. The deadline is August 15.

Additional Resources:

  • Clinicians’ Guide to Frequently Asked Questions About Lipoprotein(a) Testing
  • Researchers: win up to $40K studying effects of lipoprotein(a) on cardiovascular disease, stroke risk | American Heart Association
  • Follow AHA/ASA news on X @HeartNews

###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.   

For Media Inquiries: 214-706-1173

Michelle Rosenfeld: michelle.rosenfeld@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org 


[1] Reyes-Soffer G, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. October 14, 2021. 42(1). https://doi.org/10.1161/ATV.0000000000000147.

[2] Shah N, Mulder H, et al. Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems. JAHA. November 4, 2024. 13(21). https://doi.org/10.1161/JAHA.124.035610.

[3] Wilson D, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology. 2019. https://www.lipid.org/sites/default/files/files/Use%20of%20lipoprotein(a)%20in%20clinical%20practice(1).pdf; Tsimikas S, Marcovina S. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. JACC. August 2022. 80(9):934–946. https://www.jacc.org/doi/full/10.1016/j.jacc.2022.06.019.

More News

View More
Should Investors Lock Arms With Buffett and Dive Into POOL Stock?
July 29, 2025
Via MarketBeat
Topics Artificial Intelligence Regulatory Compliance
Tickers BRK-A BRK-B ORCL POOL
Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2
July 29, 2025
Via MarketBeat
Tickers MS T TMUS VZ
Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
July 29, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers GEV GOOGL NOW
Act Fast: These 3 Undervalued Stocks Won’t Stay Low for Long
July 29, 2025
Via MarketBeat
Tickers ALB INTC XPEV
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
July 29, 2025
Via MarketBeat
Topics Economy
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap